CMS floats Medicare payment for AI diagnostic software, proposing a new category to standardize reimbursement for algorithm-driven clinical tools.

This small-ticket transaction matters far more than its size suggests. The post Pro Medicus just struck a revolutionary AI ...

A new study published in the Journal of Neuroscience reveals that even minor cardiac dysfunction can predict microscopic tissue degradation in brain regions associated with Alzheimer's disease. This ...

Heart failure (HF) remains a pressing health concern, with rising prevalence globally. Subjectivity and ambiguity in the definition of HF and its antecedent stages have limited research, global ...

This article is authored by Dr. Ashok Punjabi is a consultant cardiologist with 40 years of non-invase and invasive ...

Daily voice recordings reveal early signs of asthma and COPD exacerbations, suggesting voice analysis could enhance remote ...

Harvey Weinsteinwas rushed to the hospital after suffering heart failure while imprisoned on Rikers Island in New York City. Weinstein was allegedly diagnosed with pneumonia, which ultimately affected ...

The FDA cleared EchoNext, the first artificial intelligence tool to detect structural heart disease before symptoms present.

(AGL) rated Buy with $177 target after a strong Q1 beat and raised guidance. Read here for a detailed investment analysis.

The Pro Medicus share price is rallying again as investors respond to the company’s latest move in healthcare AI.

CorVista Health, has announced that the American Medical Association (AMA) has granted a new Category III Current Procedural Terminology (CPT®) code for novel augmentative AI algorithmic analysis of ...

Claims-based ATTR-CM incidence increased >4-fold in Medicare (2010–2021) and ~2.7-fold in commercial insurance (2016–2022), with parallel multi-fold prevalence increases across databases. Higher rates ...